PHARMOS's net debt stood at CZK 1,245 mil and accounted for 191% of equity at the end of 2019. The ratio is down 10.3 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 201% in 2018 and a low of 191% in 2019 between 2018 and 2019. The average for the last five years was 196%.
Net debt to EBITDA was calculated at 21.7x at the end of the year.
Severity: Warning
Message: A non-numeric value encountered
Filename: src/Environment.php(418) : eval()'d code
Line Number: 18541
The company’s cost of funding amounted to 2.83% in 2019, up which is above the 5-year of 2.44%. Funding costs have “eaten” some 111% of the operating profit generated in 2019.
You can see all the company’s data at PHARMOS profile, or you can download a report on the company in the report section.
Helgi Library 
